Site Announcement
For the latest results and update on CytoDyn’s Phase 2 CRC trial and more, here’s a link to our April 30, 2026 investor update webinar
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 07/31/25 | UPLOAD | SEC-generated letter |
|
1 | |
| 07/25/25 | S-3 | Registration statement under Securities Act of 1933 |
|
36 | |
| 07/25/25 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
  |
101 |
| 05/22/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 05/22/25 | 3 | Initial statement of beneficial ownership of securities |
|
2 | |
| 05/16/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
4 | |
| 05/16/25 | 8-K | Current report |
|
 |
4 |
| 05/06/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
22 | |
| 05/06/25 | 8-K | Current report |
|
|
23 |
| 04/15/25 | 424B3 | Prospectus [Rule 424(b)(3)] |
|
34 |
